Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
02 nov. 2022 16h05 HE
|
Sana Biotechnology, Inc
Expect to file IND this year for SC291 with potential clinical data in 2023 Followed by expected INDs for SG295 and SC276 in 2023 and SC451 in 2024 with potential clinical data in 2024 Q3 2022 cash...
Sana Biotechnology to Present at September 2022 Investor Conferences
09 sept. 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
04 août 2022 16h05 HE
|
Sana Biotechnology, Inc
Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as...
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
17 juin 2022 09h00 HE
|
Sana Biotechnology, Inc
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune...
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
13 juin 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will...
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
07 juin 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory
01 juin 2022 16h05 HE
|
Sana Biotechnology, Inc
Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Next Three Years Global Cell Therapy Manufacturing Expert Snehal Patel Appointed Head of Manufacturing Veteran Regulatory...
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
12 mai 2022 17h40 HE
|
Sana Biotechnology, Inc
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice...
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
10 mai 2022 16h05 HE
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic...
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
04 mai 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...